Amgen reports 'striking' results for Xgeva in delaying prostate cancer bone metastases
This article was originally published in Scrip
Executive Summary
In reporting full results of its study 147, Amgen on 17 May not only confirmed that its 120mg dosage form of denosumab, known as Xgeva, improved median bone metastasis-free survival by 4.2 months in men with castrate-resistant prostate cancer (CRPC) versus placebo – the first time a bone-targeted drug has delayed the spread of prostate cancer to the bones – but new data showed the drug also significantly delayed the time to first bone metastasis and the time to symptomatic, or painful, bone metastasis.